Patrick John Finn Sells 10,340 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 10,340 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $496,320.00. Following the sale, the chief operating officer now directly owns 221,061 shares in the company, valued at $10,610,928. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total transaction of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The shares were sold at an average price of $43.09, for a total transaction of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $296,636.65.

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $2.77 on Wednesday, hitting $42.49. 962,117 shares of the stock were exchanged, compared to its average volume of 941,048. Twist Bioscience Co. has a fifty-two week low of $18.59 and a fifty-two week high of $60.90. The stock has a fifty day moving average of $43.86 and a 200-day moving average of $45.95.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Leerink Partners lifted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Finally, Barclays reduced their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $51.22.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Thrivent Financial for Lutherans acquired a new position in shares of Twist Bioscience during the 3rd quarter valued at $43,992,000. Point72 Asset Management L.P. lifted its stake in shares of Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after purchasing an additional 613,057 shares in the last quarter. Fred Alger Management LLC boosted its position in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after buying an additional 575,080 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Twist Bioscience by 4.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company’s stock valued at $23,717,000 after buying an additional 24,582 shares in the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Twist Bioscience by 1.8% during the 3rd quarter. New York State Common Retirement Fund now owns 482,606 shares of the company’s stock valued at $21,804,000 after buying an additional 8,529 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.